evidenceId,evidenceType,shortDesc,desc,id,lastEdit,status,gene/entrezGeneId,gene/hugoSymbol,gene/name,gene/oncogene,gene/curatedIsoform,gene/curatedRefSeq,gene/geneAliases/0,gene/geneAliases/1,gene/geneAliases/2,gene/geneAliases/3,gene/tsg,articles/0/pmid,articles/0/title,articles/0/journal,articles/0/pubDate,articles/0/volume,articles/0/issue,articles/0/pages,articles/0/authors,articles/0/elocationId,articles/0/link,articles/0/reference,articles/0/abstract,articles/1/pmid,articles/1/title,articles/1/journal,articles/1/pubDate,articles/1/volume,articles/1/issue,articles/1/pages,articles/1/authors,articles/1/elocationId,articles/1/link,articles/1/reference,articles/1/abstract,articles/2/pmid,articles/2/title,articles/2/journal,articles/2/pubDate,articles/2/volume,articles/2/issue,articles/2/pages,articles/2/authors,articles/2/elocationId,articles/2/link,articles/2/reference,articles/2/abstract,articles/3/pmid,articles/3/title,articles/3/journal,articles/3/pubDate,articles/3/volume,articles/3/issue,articles/3/pages,articles/3/authors,articles/3/elocationId,articles/3/link,articles/3/reference,articles/3/abstract,articles/4/pmid,articles/4/title,articles/4/journal,articles/4/pubDate,articles/4/volume,articles/4/issue,articles/4/pages,articles/4/authors,articles/4/elocationId,articles/4/link,articles/4/reference,articles/4/abstract,articles/5/pmid,articles/5/title,articles/5/journal,articles/5/pubDate,articles/5/volume,articles/5/issue,articles/5/pages,articles/5/authors,articles/5/elocationId,articles/5/link,articles/5/reference,articles/5/abstract,articles/6/pmid,articles/6/title,articles/6/journal,articles/6/pubDate,articles/6/volume,articles/6/issue,articles/6/pages,articles/6/authors,articles/6/elocationId,articles/6/link,articles/6/reference,articles/6/abstract,articles/7/pmid,articles/7/title,articles/7/journal,articles/7/pubDate,articles/7/volume,articles/7/issue,articles/7/pages,articles/7/authors,articles/7/elocationId,articles/7/link,articles/7/reference,articles/7/abstract,articles/8/pmid,articles/8/title,articles/8/journal,articles/8/pubDate,articles/8/volume,articles/8/issue,articles/8/pages,articles/8/authors,articles/8/elocationId,articles/8/link,articles/8/reference,articles/8/abstract,articles/9/pmid,articles/9/title,articles/9/journal,articles/9/pubDate,articles/9/volume,articles/9/issue,articles/9/pages,articles/9/authors,articles/9/elocationId,articles/9/link,articles/9/reference,articles/9/abstract
1,GENE_SUMMARY,,"KIT, a receptor tyrosine kinase, is recurrently mutated in gastrointestinal stromal tumors.",,2017-04-26,,3815,KIT,KIT proto-oncogene receptor tyrosine kinase,True,ENST00000288135,NM_000222.2,PBT,C-Kit,CD117,SCFR,False,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,
2,GENE_BACKGROUND,,"The proto-oncogene KIT encodes a type 3 transmembrane receptor tyrosine kinase. The receptor is activated through dimerization and autophosphorylation upon binding by its ligand, stem cell factor (SCF) also known as mast cell growth factor (MGF) (PMID: 9438854). KIT activation results in increased intracellular signaling through several pathways including PI3K, MAPK and STAT, ultimately leading to cell proliferation and survival (PMID: 17546049, 11896121, 22089421). For patients with wildtype gastrointestinal stromal tumors (GIST; no KIT or PDGFRA mutations), NCCN recommends testing for germline succinate dehydrogenase (SDH) mutations. About 10-15% of GISTs are wildtype; thus, the absence of a mutation does not exclude the diagnosis of GIST. In patients without KIT mutations, a subset of those with advanced GISTs benefit from imatinib (0-45% of patients) (NCCN Soft Tissue Sarcoma v.2.2017). Activating KIT mutations occur in 80 - 90% of GISTs and are distributed over multiple exons with different frequencies (exons 11 (66.1%), exon 9 (13%), exon 13 (1.2%), and exon 17 (0.6%)) (PMID:15365079, 17268243, 11719439). There are at least eight small molecule tyrosine kinase inhibitors (TKIs) targeting KIT that have been approved by the US Food and Drug Administration with the efficacy of each TKI strongly depending on the location of the activating KIT mutation (PMID: 2427414, 18955458,19164557).",,2017-08-28,,3815,KIT,KIT proto-oncogene receptor tyrosine kinase,True,ENST00000288135,NM_000222.2,PBT,C-Kit,CD117,SCFR,False,11719439,KIT activation is a ubiquitous feature of gastrointestinal stromal tumors.,Cancer research,2018-11-15T20:01:00,61,22,8118-21,Rubin BP et al,,,0001-11-15,,9438854,Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.,"Science (New York, N.Y.)",0001-01-23,279,5350,577-80,Hirota S et al,,,0001-01-23,,18955458,Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2017-11-20T20:08:00,26,33,5352-9,Heinrich MC et al,doi: 10.1200/JCO.2007.15.7461,,0001-11-20,,15365079,Biology of gastrointestinal stromal tumors.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-09-15T20:04:00,22,18,3813-25,Corless CL et al,,,0001-09-15,,11896121,Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies.,Journal of clinical oncology : official journal of the American Society of Clinical Oncology,2018-03-15T20:02:00,20,6,1692-703,Heinrich MC et al,,,2018-03-15T07:03:00,,2427414,[Local streptokinase administration in massive pulmonary embolism].,"Folia haematologica (Leipzig, Germany : 1928)",1986,113,2001-01-02,47-56,Oltmanns G et al,,,2018-01-02T19:28:00,,22089421,Gastrointestinal stromal tumours: origin and molecular oncology.,Nature reviews. Cancer,2017-11-17T20:11:00,11,12,865-78,Corless CL et al,doi: 10.1038/nrc3143,,0001-11-17,,17268243,"Current issues in gastrointestinal stromal tumors: incidence, molecular biology, and contemporary treatment of localized and advanced disease.",Current opinion in gastroenterology,2018-03-01T20:07:00,23,2,149-58,Raut CP et al,,,0001-03-01,,17546049,KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.,Oncogene,2017-11-29T20:07:00,26,54,7560-8,Bauer S et al,,,0001-11-29,,19164557,KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.,Proceedings of the National Academy of Sciences of the United States of America,2018-02-03T20:09:00,106,5,1542-7,Gajiwala KS et al,doi: 10.1073/pnas.0812413106,,0001-02-03,
